P2.09. Treatment Adherence Disparities and Clinical Outcomes of Osimertinib among Ethnic-Minority Patients with EGFR-Mutated NSCLC - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Matthew Lee
Meta Tag
Speaker Matthew Lee
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
WCLC 2023 conference
EGFR-mutated non-small cell lung cancer
ethnic-minority patients
treatment adherence
overall survival
progression-free survival
medication possession ratio
racial/ethnic groups
mortality risk
Powered By